Ladostigil is a cholinesterase enzyme inhibiting compound initially developed as a potential treatment and management for Alzheimer’s disease (AD). The Phase IIb of its trials for the treatment of AD was discontinued in 2012, when it did not meet its primary endpoint. The consensus among experts is that further studies were abandoned when it was established that Ladostigil required high doses for its cholinesterase inhibiting properties as well as its monoamine oxidase inhibiting properties to take effect.
The compound is being currently being investigated for the treatment and management of neurodegenerative diseases like Lewy body disease, Parkinson’s disease, and mild cognitive impairment (MCI). While the initial trials showed that Ladostigil is ineffective at inhibiting the enzymes at lower doses, the same trials suggested that the compound may have neuroprotective abilities.
Ladostigil was invented by Israeli researchers and Avraham Pharma owns the US and Australian patents of the compound. Avraham Pharma was founded in 2010 and its three founders are the co-inventors of Ladostigil. Two of the founders, Professor Marta Weinstock-Rosin and Professor Michael Chorev are also the co-inventors of Rivastigmine, , a drug designed for the treatment of Alzheimer’s disease and is being sold under the brand name Exelon by Novartis.
The neuroprotective properties of Ladostigil were observed to be a result of its ability to reduce oxidative stress and microglial activation, and by inhibiting pro-inflammatory cytokines. Ladostigil is currently set to begin a randomized double-blind study for its potential as a treatment for mild cognitive impairment.
During the early stages of its trial as a form of treatment and management of mild cognitive impairment, Ladostigil has shown much promise due to its neuroprotective abilities. This makes the supplementation with the compound to be a practical preventive therapy for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
Although mild cognitive impairment can be a symptom for a host of other medical conditions, Ladostigil’s potential as treatment for MCI have significant implications as there currently are no treatment for it. A cure for MCI therefore, can pave the way for more novel treatments for a variety of neurological conditions.
Hopes were also pinned on Ladostigil for it to become an effective and unique cognitive enhancer as it has both cholinergic properties and the ability to mimic the same effects as a monoamine oxidase inhibitor. However, since the cholinesterase enzyme inhibiting abilities of Ladostigil as well as its MOI-like abilities can be only achieved at very high doses, things seem to be not too promising to those who are hoping for the compound to become yet another potent nootropic agent. The final nail in the coffin for Ladostigil’s promise as a nootropic agent came with the closing of the product development for the AD program of Avraham Pharma.
- It has shown the ability to delay, prevent, and even reverse the effects of cognitive impairment.
- It has neuroprotective abilities.
- It has shown to have the anxiolytic and antidepressant properties.
- It may have other important medical applications.
- Its nootropic effects are only achievable in high doses.
- It may not work as a cognitive enhancing agent.
- It may take a little while longer for it to be available even from online suppliers.
- No tests have been done on young and healthy human subjects.
Even though Ladostigil may have shown promise at the start of the trials, it unfortunately turned out to be a disappointment not only as a treatment for Alzheimer’s disease, but a nootropic agent as well. Hopes have become high though, for its potential as a treatment for MCI. However, those who are still hoping for it to have potent nootropic properties should start looking at other novel nootropic drugs in development or be happy with the ones that are already available now.